Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.
Publication
, Journal Article
Smith, SM; Bartlett, N; Johnson, JL; Lister, J; Cashen, AF; Jung, S; Schöder, H; Egan, K; Cheson, BD
Published in: Journal of Clinical Oncology
May 20, 2010
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
8039 / 8039
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Smith, S. M., Bartlett, N., Johnson, J. L., Lister, J., Cashen, A. F., Jung, S., … Cheson, B. D. (2010). Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. Journal of Clinical Oncology, 28(15_suppl), 8039–8039. https://doi.org/10.1200/jco.2010.28.15_suppl.8039
Smith, S. M., N. Bartlett, J. L. Johnson, J. Lister, A. F. Cashen, S. Jung, H. Schöder, K. Egan, and B. D. Cheson. “Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 8039–8039. https://doi.org/10.1200/jco.2010.28.15_suppl.8039.
Smith SM, Bartlett N, Johnson JL, Lister J, Cashen AF, Jung S, et al. Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):8039–8039.
Smith, S. M., et al. “Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 8039–8039. Crossref, doi:10.1200/jco.2010.28.15_suppl.8039.
Smith SM, Bartlett N, Johnson JL, Lister J, Cashen AF, Jung S, Schöder H, Egan K, Cheson BD. Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):8039–8039.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
8039 / 8039
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences